Pathological ventricular remodeling: therapies: part 2 of 2.
about
The cardiac enigma: current conundrums in heart failure researchOngoing controversies surrounding cardiac remodeling: is it black and white-or rather fifty shades of gray?Cardiac fibroblast in development and wound healing.MiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis.Cardiac myosin binding protein-C: a novel sarcomeric target for gene therapySIRT1 functions as an important regulator of estrogen-mediated cardiomyocyte protection in angiotensin II-induced heart hypertrophy.Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.The Importance of Biological Sex and Estrogen in Rodent Models of Cardiovascular Health and DiseaseIntravenous Followed by X-ray Fused with MRI-Guided Transendocardial Mesenchymal Stem Cell Injection Improves Contractility Reserve in a Swine Model of Myocardial Infarction.Pathological ventricular remodeling: mechanisms: part 1 of 2Exercise training in adverse cardiac remodeling.Interaction between myofibroblasts and stem cells in the fibrotic heart: balancing between deterioration and regeneration.A Review of the Molecular Mechanisms Underlying the Development and Progression of Cardiac Remodeling.Specific α7 nicotinic acetylcholine receptor agonist ameliorates isoproterenol-induced cardiac remodeling in mice through TGF-β1/Smad3 pathway.Chronic heart failure: Ca(2+), catabolism, and catastrophic cell death.How cardiomyocytes sense pathophysiological stresses for cardiac remodeling.Mitochondria in Structural and Functional Cardiac Remodeling.TGFBI functions similar to periostin but is uniquely dispensable during cardiac injuryEditorial: Cardiac Remodeling: New Insights in Physiological and Pathological Adaptations.Effect of Chronic Heart Rate Reduction by I(f) Current Inhibitor Ivabradine on Left Ventricular Remodeling and Systolic Performance in Middle-Aged Rats With Postmyocardial Infarction Heart Failure.Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis.Insights into innate immune signalling in controlling cardiac remodelling.Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysisTherapeutic Effects of Wenxin Keli in Cardiovascular Diseases: An Experimental and Mechanism Overview
P2860
Q26766151-6A3CEF23-0B64-4D93-BFC2-5CD71A894EB2Q26800197-A7572417-FC0F-4132-9E8C-FCA47F43FB02Q33639215-3BAF7E05-162C-4931-8123-0AED562C7633Q33731819-D7E0A060-1548-42EE-9E97-6C529ECDB1A0Q34755677-B44FB6EC-BFEF-4FC1-98E2-BEE95BD8AD85Q34966315-190C9C6D-B4CA-4056-828C-A3BD977D349BQ35534909-20B411C5-F2BF-4F9B-8F35-01CC611C994DQ36807388-D6DC23C9-A225-4D38-9F12-0E0806C7F462Q37221593-97F57028-6B3B-4C36-8CBA-84AE2F0FEFA3Q37241166-EB5C3850-F155-4969-A394-D1130918B223Q38191440-F4B930EB-A51A-4618-A1BB-EB0DB3BAA9B4Q38191761-64BA486F-D242-48F9-A6CE-D7D5892FE70BQ38656290-ADF24CDF-4995-482A-89D6-937BB6D704EBQ38667881-26DEC9E7-6838-4C5E-AD7D-78DA322781E8Q38699105-D8759B67-7751-49E2-B4DE-1F917F23E20BQ38974621-0FCA1AB2-F37D-4F2F-A0DD-3BE084013931Q39334539-9FF55827-74F4-431A-BCB7-DD088E0D2B39Q41153678-56E6A7E2-9C67-49BC-B7B6-B1F2BB49AA5BQ42368402-9C31CD1A-923C-458E-8A86-19DE6FD0CBF4Q46031161-A1019B4D-B169-4DB3-9A25-A2D19059768AQ47094281-A75C9825-0054-49A7-9359-EA71368EA75AQ52448624-A1EE3832-B6A5-40D7-8DD1-15A1C5BB76B1Q57379205-95BA5E40-7211-46BB-9290-C2EB6818F5F5Q58762832-5E0030F0-613A-436A-A082-8E0D7B455E45
P2860
Pathological ventricular remodeling: therapies: part 2 of 2.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pathological ventricular remodeling: therapies: part 2 of 2.
@en
Pathological ventricular remodeling: therapies: part 2 of 2.
@nl
type
label
Pathological ventricular remodeling: therapies: part 2 of 2.
@en
Pathological ventricular remodeling: therapies: part 2 of 2.
@nl
prefLabel
Pathological ventricular remodeling: therapies: part 2 of 2.
@en
Pathological ventricular remodeling: therapies: part 2 of 2.
@nl
P2093
P2860
P1433
P1476
Pathological ventricular remodeling: therapies: part 2 of 2.
@en
P2093
Jana S Burchfield
Joseph A Hill
P2860
P304
P356
10.1161/CIRCULATIONAHA.113.001879
P407
P577
2013-08-01T00:00:00Z